About Our Department
The Department of Urology Surgery of the Cancer Hospital of the University of Chinese Academy of Sciences (CHUCAS) was established in 2012. Currently there are 62 opening beds in our department. It is located on the east side of the sixth floor of Building 2. Our department specializes in treating patients with genitourinary (GU) system cancers, including prostate, bladder, kidney, adrenal gland, ureter, urethra, testis, penis and so on.
Our department owns 25 medical staff including 2 chief physicians and 3 deputy chief physicians, with 3 having a doctor's degree, 2 holding doctoral candidates and 3 having master’s degree. Prof. Shaoxing Zhu, the director of the department, specializes in minimally invasive surgery and comprehensive treatment of GU cancers. He is a member of the standing Committee of the Professional Committee of Urogenital Oncology of China Anti-Cancer Association, President of Professional Committee of Urinary System Oncology of Zhejiang Society of Mathematical Medicine, Vice President of Urinary Oncology Committee of Zhejiang Physicians Association, et al.
Treatment and Technology
Our department carries out about 1000 operations of GU system tumors every year. With Multidisciplinary Team (MDT) and minimally invasive surgery as the core technology, we combine surgery with chemotherapy, radiotherapy, hormonal therapy, targeted therapy, immunotherapy and other treatments, which have greatly improved the survival rate and quality of patients with GU cancer. Most of the operations are minimally invasive surgeries such as laparoscopic cystectomy, radical prostatectomy, retroperitoneal lymph node dissection, inguinal lymph node dissection, partial nephrectomy, radical nephrectomy and nephroureterectomy, as well as some endourologic surgery including transurethral resection of bladder tumor, transurethral resection of prostate, ultrasound guided radioactive seeds implantation for prostate cancer and ureteroscopic surgery. Recently, we have performed robot-assisted surgery for urinary system tumors. The technology of minimally invasive surgery has reached the advanced level in our country. Furthermore, we have accumulated rich experiences in diagnosis and treatment of many intractable cases, such as resection of recurrent tumors, large tumors in adrenal gland, kidney, retroperitoneum and pelvis, as well as combined resection of multiple organ tumors.
Our department is equipped with a series of high quality system, including the fourth generation da Vinci Robot Surgical system, STORZ endoscopic transurethral system, laparoscopic system, pelvic floor rehabilitation training system, etc.
Research and Clinical Trials
The Department of Urologic Surgery at CHUCAS is dedicated to advancing the field of urologic oncology through innovative and groundbreaking research to improve the diagnosis and treatment of urologic conditions. In the past 5 years, our department has published 50 papers in national or above journals, including 25 SCI papers. Besides, the department has won the National Science Foundation and the foundation of Science and Technology Commission of Zhejiang. As primary authors, we were also awarded 2 times of the third prize of Science and Technology Progress of Zhejiang Provincial Health Department. As a national drug clinical trial base, we have participated in about 20 phase II or III clinical trials for antitumor drugs, which could provide some new options for patients.
Last update: Mar. 2020